In CKD, dapagliflozin reduced a composite of eGFR decline, end-stage kidney disease, or CV or renal mortality

Donald A Molony; Frederick I LeMaistre

doi:10.7326/ACPJ202102160-020

In CKD, dapagliflozin reduced a composite of eGFR decline, end-stage kidney disease, or CV or renal mortality

Ann Intern Med. 2021 Feb;174(2):JC20. doi: 10.7326/ACPJ202102160-020. Epub 2021 Feb 2.

Authors

Donald A Molony¹, Frederick I LeMaistre¹

Affiliation

¹ University of Texas McGovern Medical School, Houston, Texas, USA (D.A.M., F.I.L.).

PMID: 33524285
DOI: 10.7326/ACPJ202102160-020

Abstract

Heerspink HJ, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436-46. 32970396.

Publication types

Comment

MeSH terms

Benzhydryl Compounds
ErbB Receptors
Glomerular Filtration Rate
Glucosides / adverse effects
Humans
Kidney Failure, Chronic* / complications
Renal Insufficiency, Chronic* / complications

Substances

Benzhydryl Compounds
Glucosides
dapagliflozin
EGFR protein, human
ErbB Receptors